Skip to main content
Premium Trial:

Request an Annual Quote

Pluvita Signs On for Access to AxCell s Pathways Data

NEW YORK, Nov. 28 – Biotechnology company Pluvita has signed a three-year, non-exclusive deal for access to AxCell Bioscience’s ProChart database, which contains information on signal transduction pathways in the human proteome, AxCell said Wednesday. Financial terms of the deal were not disclosed.

The database includes the map of the WW protein domain family, a complete human domain family involved in signal transduction. ProChart also includes protein pathway information from several other domain families, such as PDZ, SH2 and SH3.

Pluvita, a small privately-held company based in Bethesda, Md., said it would use the database in a number of its research and drug discovery initiatives, in areas such as cancer, reproductive health, and diabetes.

“We have  a systems biology approach for discovering unique genes involved in pathogenesis,” said Pluvita CEO Gary Kurtzman. “Our discoveries will lead us to the identification of possible pathways, and in order to complete that you need to know what other proteins are involved. That’s what AxCell’s database will provide.”

ProChart was launched in June as part of InforMax’s GenoMax bioinformatics system. Pluvita’s subscription, though, is limited to the ProChart database.

AxCell Biosciences of Princeton, NJ, is a subsidiary of Cytogen.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.